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266a Monday, February 4, 2013PD increases hERG1 current by multiple effects, including a shift of inactiva-
tion to a more positive voltage, slowing of deactivation and an increase in sin-
gle channel open probability. The efficacy of PD was increased in proportion to
the WT:L646E subunit ratio. The Hill coefficient was 1.40 - 1.55 for all the het-
eromeric concatamers, suggesting a weak positive cooperativity for PD bind-
ing. At a fully effective concentration of PD (10mM), each WT binding site
contributes ~20% towards the maximum response of 80% enhancement of
current.
ICA increases hERG1 current by a profound attenuation of inactivation. An in-
crease in the WT:F557L subunit ratio enhanced the agonist activity of ICA
(10mM and 30mM) in a synergistic fashion. For 2WT/2F557L concatenated
channels, synergy required adjacent (as opposed to diagonal) WT subunits.
In summary, four intact binding sites per channel are required to fully activate
hERG1 by PD or ICA.
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Human ether-a-go-go related gene (hERG) channel inhibitors can be trapped in
the channels at rest. The structural peculiarities of hERG blockers that enable
trapping or alternatively resting state dissociation are currently unknown. Prop-
afenone (small molecule, MW 341 g/mol) is efficiently trapped in the closed
hERG channel pore (1). To investigate whether the size of the blocking mole-
cule plays a role in trapping we synthesized bulky propafenone derivatives con-
taining benzoyl and trimethylphenyl side chains, attached by piperazine linkers,
with molecular weights of 500 (Fba212) and 650 g/mol (Fba213) respectively.
hERG channels were expressed in Xenopus laevis oocyte and potassium cur-
rent inhibition was studied using the two - microelectrode voltage clamp
technique.
It was found: first, both compounds are potent hERG blockers with IC50 3.7mM
(Fba212) and 52mM (Fba213). Secondly, channel block by Fba212 and 213 was
prevented by mutations Y652A and F656A as previously shown for propafe-
none. Third, both propafenone derivatives were trapped at rest. To obtain
insights into the molecular mechanism of channel block docking experiments
with Fba212 and Fba213 in closed and open conformation were performed.
Both compounds interact with the propafenone binding site (Y652A and
F656A). Fba213 was found to exceed the size of the closed channel cavity of
our hERG homology model. We conclude that drug trapping in hERG channels
does not necessarily require full closure of the activation gate.
1. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC,
Mitcheson JS.
Mol Pharmacol. 2004 Nov; 66(5):1201-12.
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ICA105574 (3-Nitro-N-(4-phenoxyphenyl)-benzamide) activates hERG1
(Kv11.1) channels by reducing inactivation, but inhibits hEAG1 (Kv10.1)
channels by inducing inactivation. using chimeric ERG-EAG constructs, we
found that the channel-specific response to ICA105574 is mediated by the
pore region (S5-pore helix-S6). Simulated docking of ICA105574 on a molec-
ular model of hEAG1 coupled with alanine mutagenesis indicates that similar
to hERG1, ICA105574 binds to a hydrophobic region confined by the S5/S6/
pore helix of one subunit and S6 of adjacent subunit in hEAG1 channels. Based
on the putative ICA binding site and protein sequence alignment, a triple
mutant of hEAG1 (M431F/M458L/L463M hEAG1) was designed to make
the ICA binding region in hEAG1 homologous to hERG1. ICA inhibited the
triple mutant similar to WT-hEAG1, indicating that the amino acid differences
within the putative ICA binding region do not determine the reciprocal func-
tional response to ICA. A single mutation in S5 (F557L), pore helix (L622C)
or S6 (Y652A) of hERG1 eliminates the activity of ICA on hERG1 (Garg, et
al 2011, Mol. Pharm.). The equivalent mutations in hEAG1 affect inactivation
differentially and result in very different responses to ICA. First, Y464A in-
duced inactivation of hEAG1 channels and this gating was accentuated by
ICA. Second, ICA is a partial agonist of F359L and L434C mutant channels.
We recently proposed a tripartite model of slow inactivation for hEAG1 that
involves interaction of the same three residues. We conclude that ICA bindsto the same site in hEAG1 and hERG1 channels, and that the functional conse-
quences are determined by the underlying (fast or slow) mode of selectivity-
filter mediated inactivation.
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The human ether-a-go-go related gene 1 (hERG1) potassium ion channel is
a key element for the cardiac delayed rectified potassium current IKr and it
plays an important role in the normal repolarization of the action potential.
Diverse types of organic compounds used both in common cardiac and noncar-
diac medications can reduce the IKr and may lead to ventricular arrhythmia.
Therefore, several approved drugs have been withdrawn from the market
because of their effects on QT interval prolongation. Since most of these drugs
have high potency for their principal targets, ‘‘rehabilitation’’ studies for de-
creasing their high hERG1 blocking affinities while keeping them active at
the binding site of their targets may lead re-use of these drugs. For this aim,
a gastroprokinetic agent, cisapride, is studied. Cisapride is withdrawn from
the market because of its high hERG1 blocking affinity. In this study, analyses
of fragment interactions of cisapride at the human A2A adenosine receptor and
hERG1 central cavities is investigated using in silico applications (molecular
docking, molecular dynamics simulations, de novo drug design) and novel
and safer (with low hERG1 blocking affinities) of cisapride derivatives are pro-
posed for their synthesis and their biological tests.
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The human Ether-a-go-go Related Gene (hERG) encodes Kv11.1 and underlies
the rapidly activating delayed rectifier Kþ current in the heart, and loss-of-
function hERG mutations cause the type 2 long QT syndrome (LQT2). The
majority of LQT2-linked missense mutations decrease the trafficking of
Kv11.1. An important finding is drugs that bind to Kv11.1 and block current
(IKv11.1) can correct the trafficking for most of these mutations (pharmacolog-
ical correction). We tested the hypothesis that pharmacological correction in-
creases the trafficking of mutant LQT2 channels from the Endoplasmic
Reticulum (ER). Voltage-clamping and Western blotting experiments of
HEK293 cells expressing the trafficking-deficient LQT2 mutation G601S
showed that pharmacological correction still occurred in cells treated with the
protein synthesis inhibitor cycloheximide. Confocal analyses of HEK293 cells
stably expressing wild type Kv11.1 or G601S showed that G601S is selectively
stored in an intermediate ER compartment with BAP31. The intermediate
BAP31 compartment does not overlap with the perinuclear ER compartment,
transitional ER compartment, or the ER Golgi Intermediate Compartment.
Treating cells in E-4031, a drug that corrects G601S trafficking, decreased
G601S co-localization with intermediate BAP31 compartment and increased
G601S immunostaining at the cell surface membrane. Additional experiments
showed that treating cell in E-4031 for as little as 30 min was sufficient to
caused the pharmacological correction of IKv11.1 for many hours. Together
these data demonstrate that a steady-state subpopulation of LQT2 channels is
stored separately in the BAP31 transitional ER compartment and their func-
tional expression is readily corrected by E-4031 treatment.
1370-Pos Board B262
LQT2 Nonsense Mutations Generate Trafficking Deficient N-Terminally
Truncated Channels by the Reinitiation of Translation
Matthew Stump, Qiuming Gong, Zhengfeng Zhou.
OHSU, Portland, OR, USA.
Long QT syndrome type 2 (LQT2) is caused by mutations in the human ether-
a-go-go related gene (hERG). The reinitiation of translation has recently been
reported as a novel pathogenic mechanism of LQT2 by which early PTC mu-
tations generate N-terminally truncated channels with altered gating properties.
We have previously shown that hERG transcripts containing the Q81X muta-
tion were translated at the downstreamM124 codon following premature termi-
nation and generated channels that exhibited increased deactivation kinetics
and decreased resurgent outward current during action potential repolarization.
We have now identified two additional LQT2 nonsense mutations C39X and
C44X that escape nonsense mediated mRNA decay by the reinitiation of trans-
lation. Unlike the Q81X channels, which are expressed at the cell surface,
